VWF Antibodies

The monomeric form of Von Willebrand factor (VWF) has a molecular weight of approximately 220 kDa. This protein is primarily synthesized and released by endothelial cells, which line the blood vessels, and megakaryocytes, which are precursors to platelets. VWF has two main functions in blood clotting: platelet adhesion and stabilization of clotting factor VIII.

Von Willebrand Disease (VWD) is a hereditary bleeding disorder caused by a deficiency or dysfunction of this factor. It can lead to prolonged bleeding after injury or surgery and may involve spontaneous bleeding in severe cases.

Antibodies against VWF are used in research to study the expression, structure, and function of the Von Willebrand factor. In diagnostics, immunological assays, such as enzyme-linked immunosorbent assays (ELISAs), using these antibodies can help assess this factor’s quantity and functionality in patient samples.

Synonyms

von Willebrand factor, F8VWF|VWD

Research Areas

Apoptosis, Autophagy, Breast Cancer, Cancer, Cardiovascular, Cell Biology, Cellular Markers and Tags, Developmental Biology, Endocrine, Epigenetics, Gastrointestinal Tract, Hypoxia, Immuno Oncology, Immunology, Kidney, Lymphatic, Metabolism, Microbiology, Muscle, Neuroscience, Pancreatic Cancer, Prostate Cancer, Skin, Stem Cell, AKT Signaling, Angiogenesis, Articular Cartilage Extracellular Matrix, B Cell Markers, Basal Cell Marker, BBB VCAM-1 Signaling, Bladder Cancer, Cardiac Stem Cells, Colon Cancer, Colorectal Cancer, Complement System, CTLA-4 blockade immunotherapy, Cytokine Signaling, Defective Intrinsic Apoptosis, Dendritic Cell Marker, Digestion, Endothelial Cell Marker, Hematopoietic Stem Cells, Immune checkpoint, Infectious Disease, Lipid Metabolism, Lung Cancer, MAPK Signaling, Mast Cell Marker, Melanoma, Mesenchymal Stem Cell Differentiation, Mitochondria Marker, Neural Stem Cells, Neuroinflammation, Nuclear Marker, Oncology, Ovarian Cancer, PD-1 blockade immunotherapy, Signal Transduction, Stem Cell Differentiation, Transcription Factors

VWF

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK